Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
Novel approaches including gene editing are creeping towards approval.
How can the company wring the most value from Pyrukynd?
Will upping the dose and changing the primary endpoint pay off?
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.